Quick Answer
Survodutide is an experimental weight loss drug from Boehringer Ingelheim. It works by targeting two receptors — GLP-1 and glucagon — which is why it is called a dual agonist. Trial data shows weight loss up to 19% of body weight, putting it in the same range as tirzepatide (Mounjaro/Zepbound). Two Phase 3 trials — SYNCHRONIZE-1 (obesity) and SYNCHRONIZE-MASLD (liver disease) — reported positive results on June 7, 2026, and were presented at ADA 2026. Results were also published in Nature Medicine. But survodutide is not available yet.
How Survodutide Works
Most GLP-1 drugs target one receptor (GLP-1). Survodutide targets two:
- GLP-1 receptor: Reduces appetite, slows digestion, improves blood sugar (same mechanism as Ozempic and Wegovy)
- Glucagon receptor: Increases energy expenditure and fat burning
The glucagon part is what makes survodutide different. Glucagon normally raises blood sugar, but at the right dose, it also increases how many calories your body burns. By combining GLP-1 (less appetite) with glucagon (more calorie burning), survodutide attacks weight from two directions: reduced intake and increased expenditure.
Weight Loss Results So Far
Phase 2 trial data (46 weeks):
| Dose | Weight Loss |
|---|---|
| 0.6 mg | ~7% |
| 2.4 mg | ~11% |
| 4.8 mg | ~15% |
| 7.2 mg | ~19% |
Phase 3 emerging data (as of May 2026):
Boehringer Ingelheim has reported early Phase 3 results in MASH (fatty liver disease) patients. Key findings:
- Survodutide met all primary endpoints in the MASH Phase 3 trial
- Up to 19% weight loss in the highest-dose arms — consistent with Phase 2
- Significant improvement in liver fibrosis and MASH resolution
- Full Phase 3 obesity trial results are still pending
Phase 3 SYNCHRONIZE results (June 7, 2026):
On June 7, 2026, Boehringer Ingelheim reported results from two Phase 3 trials and presented them at ADA 2026. Results were published in Nature Medicine.
SYNCHRONIZE-1 (obesity):
- Met co-primary endpoints in adults with obesity or overweight without type 2 diabetes
- Achieved sustained weight loss at the highest dose — described as "substantial" per Boehringer Ingelheim's announcement
- Specific percentage data pending full publication
SYNCHRONIZE-MASLD (liver disease):
- 34% visceral fat reduction — fat around internal organs, which is metabolically the most harmful type
- 63% liver fat reduction — directly relevant for fatty liver disease (MASLD/MASH)
- Minimized lean mass loss — a differentiator vs other GLP-1s, which can cause significant muscle loss
- This is the first GLP-1-class drug to show such strong MASH/MASLD data in Phase 3
The liver disease angle is significant. MASLD (metabolic dysfunction-associated steatotic liver disease) and its progressive form MASH affect millions of people with obesity, and there are very few effective treatments. Survodutide's glucagon mechanism appears to target liver fat directly — something GLP-1-only and GLP-1/GIP drugs do not do as effectively.
For context:
- Wegovy (semaglutide): ~15% average weight loss
- Zepbound (tirzepatide): ~20% average weight loss
- Retatrutide (experimental): up to 28.7% in Phase 3
Survodutide's top-end results are impressive but not clearly better than what's already available. The full Phase 3 obesity data — when published — will tell us more.
What Else Survodutide May Treat
Boehringer Ingelheim is also testing survodutide for MASLD/MASH (metabolic dysfunction-associated steatotic liver disease, formerly called NAFLD/NASH) — a type of fatty liver disease common in people with obesity and diabetes.
Phase 3 SYNCHRONIZE-MASLD data now shows:
- 63% liver fat reduction
- 34% visceral fat reduction
- Significant improvement in liver fibrosis and MASH resolution
- Minimized lean mass loss — a notable advantage over other GLP-1s
If approved for MASLD/MASH, survodutide would be one of the first GLP-1-based treatments for fatty liver disease — a major unmet need, given that MASLD affects an estimated 30% of adults in the US.
Side Effects
Based on Phase 2 and early Phase 3 data, side effects are similar to other GLP-1s:
- Nausea — most common, especially when starting or increasing dose
- Vomiting
- Diarrhea
- Constipation
The dual mechanism (glucagon agonism) doesn't appear to cause significantly different side effects compared to single GLP-1 agonists like Ozempic. Phase 3 data continues to confirm this.
How It Compares
| Feature | Survodutide | Ozempic/Wegovy | Mounjaro/Zepbound | Retatrutide |
|---|---|---|---|---|
| Mechanism | GLP-1 + glucagon | GLP-1 only | GLP-1 + GIP | GLP-1 + GIP + glucagon |
| Max weight loss (trials) | ~19% | ~15% | ~20% | ~28.7% |
| Dosing | Weekly injection | Weekly injection | Weekly injection | Weekly injection |
| FDA approved | No | Yes | Yes | No |
| Available now | No | Yes | Yes | No |
The key difference: Mounjaro/Zepbound targets GLP-1 + GIP. Survodutide targets GLP-1 + glucagon. Both dual-agonist approaches seem to produce more weight loss than GLP-1 alone, but through different pathways. Retatrutide targets all three — and shows the highest numbers so far.
When Could It Be Available?
Survodutide is in phase 3 trials as of June 2026. Two SYNCHRONIZE trials (obesity and MASLD) reported positive results on June 7, 2026 and were published in Nature Medicine. Timeline:
- Phase 3 data readouts: SYNCHRONIZE-1 and SYNCHRONIZE-MASLD both positive (June 2026). Additional Phase 3 trials may still be ongoing.
- FDA submission: If trials succeed, submission could happen in 2027
- Approval decision: 6-10 months after submission
- Earliest possible availability: 2027-2028
This is an optimistic timeline. Drug development often takes longer than expected. But the MASH trial results are a positive sign.
Should You Wait for Survodutide?
No. If you need weight loss help now, talk to your doctor about currently available options. Ozempic, Wegovy, Mounjaro, Zepbound, and Foundayo are proven, FDA-approved, and available today. Waiting 1-2+ years for an experimental drug that may or may not be better isn't a good strategy when effective treatments already exist.
If survodutide turns out to be meaningfully better, you can always switch later.
Bottom Line
Survodutide is a promising dual GLP-1/glucagon agonist with weight loss results similar to existing medications. It may also treat fatty liver disease — Phase 3 MASH data looks strong. But it's years away from being available, and it's not clear yet whether it offers meaningful advantages over Mounjaro/Zepbound.
If you're interested in GLP-1 medications, start with what's available now and keep an eye on pipeline drugs like survodutide, retatrutide, and CagriSema for future options.
If you start a GLP-1 injection now, basic supplies like alcohol prep pads and a sharps container are what you will need from day one. A protein powder can also help you hit protein goals while your appetite adjusts.
GLPSpot may earn from qualifying purchases.
This article is for informational purposes only and does not constitute medical advice. Survodutide is not FDA-approved. Always talk to your healthcare provider before starting any medication.
